CRESCENDO: Study to Evaluate the Efficacy and Safety of AZD4831 in Moderate to Severe COPD
We have now commenced a new trial to assess the AstraZeneca drug AZD4831 for its efficacy and safety in patients with Chronic Obstructive Pulmonary Disease (COPD)
This trial is sponsored and funded by AstraZeneca and led at Nottingham University Hospital by Professor Charlotte Bolton.
A Phase IIa Randomised, Double-Blind, Placebo Controlled, Parallel Arm, Multi Centre Study to Evaluate the Efficacy and Safety of AZD4831, for 12-24 weeks, in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
What is this study about?
We are doing this study to learn more about an investigational drug called AZD4831, to see if the study drug works and is safe for the treatment of COPD and to better understand the studied disease and associated health problems. Some parts of this study are experimental which means they have not been fully tested.
AZD4831 is a myeloperoxidase (MPO) inhibitor, which means that it reduces the effect of MPO. There is evidence that MPO is taking part in the promoting of lung inflammation and injury in animals exposed to cigarette smoke and high concentrations of (activated) MPO are associated with the progression of COPD in humans.
Therefore, this study will evaluate whether treating patients with COPD with AZD4831 will reduce the periods when your COPD gets worse (exacerbations) and improves your symptoms, quality of life and lung functions.
If you have any co-morbidities these are also anticipated to be improved. AZD4831 is a 5 mg tablet, taken orally, daily (in the mornings). About 288 people will take part in this study, aged between 40 to 80 years who are either current smokers or used to smoke and have been taking the same inhaled COPD medication for at least 3 months.
For more information, Contact: Tina.Wilkinson@nuh.nhs.uk